Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 8
2013 8
2014 5
2015 8
2016 10
2017 13
2018 14
2019 6
2020 15
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

93 results
Results by year
Filters applied: . Clear all
Page 1
Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D, Mascarenhas J. Tremblay D, et al. Expert Rev Hematol. 2018 Sep;11(9):707-714. doi: 10.1080/17474086.2018.1500456. Epub 2018 Jul 19. Expert Rev Hematol. 2018. PMID: 30001163 Review.
Areas covered: This review will describe the preclinical rationale for JAK2/FLT3 inhibition, review the pharmacology of pacritinib, and detail available clinical data for pacritinib treatment of myelofibrosis. ...Improvements in splenomegaly and symptom burden were …
Areas covered: This review will describe the preclinical rationale for JAK2/FLT3 inhibition, review the pharmacology of pacritinib, a …
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Mascarenhas J, et al. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. JAMA Oncol. 2018. PMID: 29522138 Free PMC article. Clinical Trial.
Pacritinib (arms combined) was more effective than BAT for 35% or more SVR (27 patients [18%] vs 2 patients [3%]; P = .001) and had a nonsignificantly greater rate of 50% or more reduction in TSS (37 patients [25%] vs 10 patients [14
Pacritinib (arms combined) was more effective than BAT for 35% or more SVR (27 patients [18%] vs 2 patients [3%]
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN. Mesa RA, et al. Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20. Lancet Haematol. 2017. PMID: 28336242 Clinical Trial.
The most common grade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and diarrhoea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11
The most common grade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and …
Pacritinib in Patients With Myelofibrosis.
Suzuki S, Tsuda K, Tanimoto T. Suzuki S, et al. JAMA Oncol. 2018 Dec 1;4(12):1786-1787. doi: 10.1001/jamaoncol.2018.4830. JAMA Oncol. 2018. PMID: 30422169 No abstract available.
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW, Al-Fayoumi S, Taylor J, Velichko S, O'Mahony A. Singer JW, et al. PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019. PLoS One. 2019. PMID: 31560729 Free PMC article.
To provide further translational insights into clinical outcomes, we compared phenotypic biomarker profiles of ruxolitinib, fedratinib, momelotinib, and pacritinib in the BioMAP Diversity PLUS panel of 12 human primary cell systems designed to recapitulate key aspec …
To provide further translational insights into clinical outcomes, we compared phenotypic biomarker profiles of ruxolitinib, fedratinib, mome …
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Hatzimichael E, Tsolas E, Briasoulis E. Hatzimichael E, et al. J Blood Med. 2014 Aug 19;5:143-52. doi: 10.2147/JBM.S51253. eCollection 2014. J Blood Med. 2014. PMID: 25170285 Free PMC article. Review.
Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinase 3 providing potential in the treatment of hematological malignancies such as myeloproliferative neoplasias, acute myeloid leukemia,
Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinas
Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y, McLornan DP, Harrison CN. Beauverd Y, et al. Expert Opin Pharmacother. 2015;16(15):2381-90. doi: 10.1517/14656566.2015.1088831. Expert Opin Pharmacother. 2015. PMID: 26389774 Review.
MF is often characterised by debilitating symptoms and JAK inhibitors (JAKIs) have revolutionised available therapeutic options. Ruxolitinib, a JAK1 and 2 inhibitor, is the only currently approved agent. Several other JAKIs are undergoing evaluation in the clinical trial s …
MF is often characterised by debilitating symptoms and JAK inhibitors (JAKIs) have revolutionised available therapeutic options. Ruxolitinib …
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Tremblay D, Mesa R, Scott B, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Tremblay D, et al. Blood Adv. 2020 Dec 8;4(23):5929-5935. doi: 10.1182/bloodadvances.2020002970. Blood Adv. 2020. PMID: 33275766 Free PMC article.

The intention-to-treat response rate was significantly higher on the pacritinib arm for JAK2V617F- disease (23.0% vs 0%; P = .033), and for the lowest allele burden quartiles (0%-25%: 20.9% vs 0%, P < .001; 25%-50%: 15.4% vs 0%, P = .020). There wer

The intention-to-treat response rate was significantly higher on the pacritinib arm for JAK2V617F- disease (23.0% vs 0%; P = . …
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA, Odenike O. Patel AA, et al. Curr Hematol Malig Rep. 2020 Dec;15(6):409-418. doi: 10.1007/s11899-020-00596-z. Curr Hematol Malig Rep. 2020. PMID: 32780250 Review.
However, increased rates of transfusion independence have been noted with momelotinib. Pacritinib has been studied in myelofibrosis patients with significant baseline anemia and thrombocytopenia; these trials support the use of pacritinib in myelofibrosis patients w …
However, increased rates of transfusion independence have been noted with momelotinib. Pacritinib has been studied in myelofibrosis p …
93 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page